Drug Monograph

Drug/Drug Class:	**Dyanavel® XR(amphetamine) extended release suspension/ ADHD**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Dyanavel® XR is an extended release suspension containing 2.5 mg amphetamine base per ml respectively.
Manufacturer:	Tris Pharma, Inc., Monmouth Junction, NJ 08852
Indications:	Dyanavel® XR is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Costs:	$1.96 per ml of Dyanavel® XR. Wholesale Acquisition Cost
Summary of Findings:	The Division recommends adding this drug to the current ADHD clinical edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Under Solicitation ☒ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer, Pharm.D.
Date: May 18, 2016

© 2016 Xerox Heritage, LLC All Rights Reserved.